ASX 200 lunch update: GrainCorp jumps on earnings upgrade, Pro Medicus signs $32m deal

Here's what is happening on the ASX 200 on Friday…

Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

At lunch on Friday, the S&P/ASX 200 Index (ASX: XJO) is on course to snap its losing streak and end the week on a positive note. The benchmark index is up 0.6% to 7,489.1 points.

Here's what is happening on the ASX 200 today:

GrainCorp upgrades guidance

The GrainCorp Ltd (ASX: GNC) share price hit a record high this morning following an earnings guidance update. The release notes that the company has been benefiting from significant ongoing global demand for Australian grain and oilseeds. It also notes that planting conditions for the upcoming east coast Australian winter crop are favourable. All in all, this has led to management upgrading its earnings guidance for FY 2022.

Pro Medicus signs major contract

The Pro Medicus Limited (ASX: PME) share price is rising today. This has been driven by news that the health imaging technology company has won a major new contract. According to the release, the company's US business, Visage Imaging, has signed a $32 million, eight-year contract with Inova Health System.

Ampol update

The Ampol Ltd (ASX: ALD) share price is pushing higher on Friday. This follows news that the New Zealand Commerce Commission has approved the sale of its Gull NZ business to Allegro. This paves the way for Ampol to complete the acquisition of Z Energy Ltd (ASX: ZEL).

Best and worst ASX 200 performers

The best performer on the ASX 200 has been the Paladin Energy Ltd (ASX: PDN) share price with a 10% gain. Paladin and other uranium shares are charging higher today. Going the other way, the worst performer on the ASX 200 has been the IGO Ltd (ASX: IGO) share price with a 2.5% decline. This morning UBS initiated coverage on IGO with a sell rating and $12.65 price target.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Pro Medicus Ltd. The Motley Fool Australia owns and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Broker Notes

10 Aussie stocks to buy in FY 2026

Let's see which shares analysts think could be buys in the upcoming financial year.

Read more »

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing end to the trading week for investors this Friday.

Read more »

A young boy points and smiles as he eats fried chicken.
Share Gainers

3 ASX All Ords shares smashing the benchmark this week

Investors are sending these three ASX All Ords shares rocketing 18% to more than 29% this week. But why?

Read more »

watch
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Disappointed man with his head on his hand looking at a falling share price his a laptop.
Share Fallers

Why APA, Flight Centre, Reece, and Transurban shares are falling today

These shares are having a tough finish to the week. But why?

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Alliance Aviation, BHP, Boss Energy, and Orthocell shares are racing higher

These shares are ending the week on a positive note. But why?

Read more »

Mum playing with her baby boy holding him on her tummy as she lays down while smiling about the Bubs share price going up today
Broker Notes

Following two unfortunate incidents, what's Macquarie's price target on Monash IVF shares?

Is Monash IVF a buying opportunity?

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Broker Notes

Macquarie tips 18% return for this ASX 200 stock

The broker thinks this blue chip's profits are going to rebound in FY 2026.

Read more »